Pharmacy & Therapeutics - April 2008 - (Page 230) Demonstrated efficacy in Black patients BYSTOLIC provides significant BP reductions in Black patients3* Reductions From Baseline in Mean DBP and SBP at Trough3 Placebo (n=49) SBP DBP BYSTOLIC 5 mg (n=50) SBP DBP BYSTOLIC 10 mg (n=51) SBP DBP BYSTOLIC 20 mg (n=50) SBP DBP BYSTOLIC 40 mg (n=51) SBP DBP 0 Change From Baseline (mm Hg) -2 -4 -6 -8 -10 -12 -14 -3.6 -4.4 -5.9‡ -9.1† P 0.005 vs placebo NS § P=0.05 vs placebo † ‡ -9.1† -10.3 † -10.2 § -9.6† -10.6 † -12.0† Results from a U.S. phase III, 3-month, multicenter, placebo-controlled, randomized, double-blind, parallel-group study of BYSTOLIC monotherapy for the treatment of mild to moderate hypertension in Black patients (N=300). Mean values at baseline: sitting DBP at trough, 100.4 mm Hg; sitting SBP at trough, 152.9 mm Hg. A high percentage of Black patients respond to BYSTOLIC therapy3 || n 58% to 64% of Black patients responded to therapy across the recommended dosing range3 *Effectiveness was established in Black patients, but as monotherapy the magnitude of effect was somewhat less than in Caucasians. || Response defined as DBP <90 mm Hg or DBP reduction ≥10 mm Hg from baseline.
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.